Growing Bump on the Back of Neck: Evaluation and Management
A growing neck mass in an adult requires immediate risk stratification for malignancy, and if any high-risk features are present, you should order contrast-enhanced CT or MRI of the neck and refer to otolaryngology—do not prescribe antibiotics or adopt a "wait and see" approach unless clear signs of bacterial infection are present. 1
Initial Risk Stratification
The first critical step is determining malignancy risk based on specific historical and physical examination features. Most adult neck masses are neoplastic, not infectious 1.
High-Risk Historical Features (Any ONE qualifies as high-risk):
- Mass present ≥2 weeks without significant fluctuation or uncertain duration 1
- No history of recent infection to explain the mass 1
- Age >40 years (especially with tobacco/alcohol use) 1
- Associated symptoms: throat pain, dysphagia, voice change, unexplained weight loss, unilateral ear pain, or hearing loss 1
High-Risk Physical Examination Features (Any ONE qualifies as high-risk):
- Size >1.5 cm 1
- Firm consistency 1
- Fixed to adjacent tissues (reduced mobility) 1
- Ulceration of overlying skin 1
Important caveat: The description "growing bump" inherently suggests a mass present for some duration, which should trigger high-risk evaluation unless it's clearly been <2 weeks with obvious infectious signs 1.
Management Algorithm for High-Risk Patients
Step 1: Imaging (STRONG recommendation)
Order contrast-enhanced CT of the neck (or MRI with contrast as alternative) 1, 2. This is a strong recommendation from the American Academy of Otolaryngology-Head and Neck Surgery guidelines 1, 2. Do not delay imaging while waiting for other tests.
Step 2: Specialist Referral
Refer to otolaryngology for targeted physical examination including visualization of the larynx, base of tongue, and pharynx 1. This specialized examination is essential because neck masses may represent metastatic disease from head and neck primary tumors 1.
Step 3: Tissue Diagnosis
If diagnosis remains uncertain after imaging, fine-needle aspiration (FNA) is strongly recommended over open biopsy 1. FNA provides cytology with sensitivity 77-97% and specificity 93-100% for malignancy detection 3.
Critical pitfall: Even if imaging suggests a cystic mass, continue evaluation until diagnosis is confirmed—do not assume benignity 1. Cystic neck masses can be malignant 1.
Step 4: If FNA and Imaging Are Non-Diagnostic
Proceed to examination of upper aerodigestive tract under anesthesia before considering open biopsy 1, 2. This prevents the risk of seeding tumor cells and allows comprehensive mucosal evaluation 1, 2.
Management for Low-Risk Patients
If the patient has none of the high-risk features above AND there are clear signs of bacterial infection (warmth, erythema, localized tenderness, fever), antibiotics may be appropriate 1.
For patients without high-risk features and no infection:
- Document a specific follow-up plan (not just "follow up as needed") 1
- Educate patient on red flag criteria that would trigger immediate re-evaluation: mass enlargement, development of firmness/fixation, new associated symptoms, or persistence beyond 2 weeks 1
- Re-examine within 2 weeks to assess for resolution 1
Critical Pitfalls to Avoid
Do NOT routinely prescribe antibiotics for neck masses without clear infectious signs—this delays cancer diagnosis and promotes resistance 1
Do NOT assume posterior neck location means benign etiology—while the guidelines focus on lateral neck masses, any growing neck mass requires the same systematic evaluation 1
Do NOT perform open biopsy before imaging and specialist evaluation—this can complicate subsequent cancer treatment if malignancy is present 1, 2
Do NOT rely on size alone—while masses >1.5 cm are higher risk, smaller masses with other concerning features (firmness, fixation, duration >2 weeks) also warrant full workup 1, 4
Evidence Quality Note
These recommendations come from the 2017 American Academy of Otolaryngology-Head and Neck Surgery clinical practice guidelines 1, which represent the most authoritative and recent guideline-level evidence for this clinical scenario. The strong recommendations for imaging and FNA are based on their critical role in preventing delayed cancer diagnosis, which directly impacts mortality and morbidity 1.
Recent research confirms that malignancy rates increase significantly with age (8.4% in patients ≥70 years vs 2.1% in <40 years) and with increasing mass size 4, reinforcing the guideline's risk stratification approach.